Ascendis Pharma is applying its innovative TransCon technology to develop a pipeline of best‐in‐class therapeutics that address significant unmet needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. In addition to our current pipeline of three rare disease endocrinology candidates, we have established oncology as our second therapeutic area of focus.
The Ascendis Pharma pipeline includes TransCon hGH, for which we have completed the phase 3 heiGHt Trial evaluating once-weekly TransCon hGH compared to a daily hGH in children with pediatric GHD. In March 2019, top-line data were reported for this trial, which met its primary endpoint. Ascendis Pharma is also developing two additional rare disease product candidates, TransCon PTH and TransCon CNP. In addition to its internal programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its partners. These collaborations are with Sanofi in the field of diabetes and Roche Genentech in the field of ophthalmology.
Ascendis Pharma is headquartered in Copenhagen, Denmark, maintains an office in Palo Alto, California and has research and development facilities in Heidelberg, Germany and Copenhagen, Denmark.
TransCon Technology Platform
Learn how we’re using our innovative TransCon technology (short from “transient conjugation”) to create best-in-class products to address unmet patient needs. Watch Video